Breakthroughs that
See news releases about Etira, our stellar team,
Positive preclinical data presented at AACR 2023
News Dallas, Texas. April 18, 2023:
Etira is pleased to announce that multiple abstracts related to their licensed products showed encouraging preclinical activity in metastatic breast cancer and ovarian cancer. The data, presented…
Etira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award
NewsDallas, Texas. April 17, 2023:We are excited to congratulate one of our founders, Dr. Ratna Vadlamudi, Professor and Vice Chair for Research, Division of Reproductive Research, Department of Obstetrics & Gynecology, Long School of…
Preclinical data on TNBC presented at SABCS 2022
NewsDallas, Texas. December 9, 2022:
Etira is pleased to report the abstract related to ERX-41 validating its activity in Triple negative breast cancer was presented at the San Antonio Breast Cancer Symposium (SABCS). The SABCS is one of the world's…
Etira founder Dr. Jung-Mo Ahn highlighted in local press
NewsDallas, Texas. October 31, 2022. We are pleased to share two news articles from Dallas that describe how our brilliant chemist and founder, Dr. Jung-Mo Ahn discovered ERX-41. In his words, Dr. Ahn describes the discovery of ERX-41 as “It’s…
Oncology Times Highlights ERX-41
NewsDallas, Texas. October 10, 2022:etiraRx's lead drug candidate, ERX-41 has been highlighted in the most recent edition of Oncology Times. In an article entitled "Molecule Targets Vulnerability in Triple-Negative Breast Cancer," Dibash Kumar…
Where to find us
Boston Office:
75 Kneeland Ave, 14th Floor
Boston. MA. 02111
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247